Cited 0 times in
First-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): A phase 3, randomized, double-blind study.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.